(Q45958279)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19545976%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

title

Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19545976%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

0 references

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19545976%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

7

Jeffrey Lieberman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19545976%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1

Robert A Rosenheck

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19545976%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

author name string

Vicki G Davis

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19545976%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Sonia M Davis

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19545976%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Joseph McEvoy

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19545976%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Marvin Swartz

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19545976%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

language of work or name

English

0 references

publication date

1 August 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19545976%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

published in

Schizophrenia Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19545976%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

volume

113

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19545976%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19545976%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

page(s)

12-18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19545976%20AND%20SRC:MED&resulttype=core&format=json

Chlorpromazine equivalent doses for the newer atypical antipsychotics

1 February 2020

cites work

1 reference

12 December 2020

The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development

1 reference

12 December 2020

Changing environments and alternative perspectives in evaluating the cost-effectiveness of new antipsychotic drugs

1 reference

12 December 2020

Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy

1 reference

12 December 2020

The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.

1 reference

12 December 2020

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

12 December 2020

Interpreting the efficacy findings in the CATIE study: what clinicians should know.

1 reference

12 December 2020

Commentary on the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE).

1 reference

12 December 2020

Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia

1 reference

12 December 2020

Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.

1 reference

12 December 2020

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

1 reference

12 December 2020

Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia.

1 reference

12 December 2020

Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study

1 reference

12 December 2020

Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia

1 reference

12 December 2020

Extrapyramidal side-effects of antipsychotics in a randomised trial

1 reference

12 December 2020

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

12 December 2020

A rating scale for extrapyramidal side effects

1 reference

12 December 2020

The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome

1 reference

12 December 2020

Risperidone in the treatment of schizophrenia

1 reference

12 December 2020

Long-term high-dose neuroleptic treatment: who gets it and why?

1 reference

12 December 2020

10.1016/J.SCHRES.2009.06.002

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19545976%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19545976%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

PubMed publication ID

19545976

1 reference